-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Background: Type 1 diabetes is caused by the destruction of β-cells mediated by autoimmunity
Type 1 diabetes is caused by the destruction of β-cells mediated by autoimmunity
Research results: Patients were screened and registered between February 12, 2014 and May 19, 2016
Figure 1 The c-peptide AUC represents the response to MMTT; the 4-h mixed meal tolerance test obtained the average 2-h C-peptide AUC with a compliance of 90%
Figure 1 The c-peptide AUC represents the response to MMTT; the 4-h mixed meal tolerance test obtained the average 2-h C-peptide AUC with a compliance of 90%
Figure 2 Insulin use and HbA1c levels; N is the number of patients with available data
Figure 2 Insulin use and HbA1c levels; N is the number of patients with available data
Figure 3 MMTT response; 2h blood glucose (A) and 2h serum insulin secretion AUC (B) after MMTTS
Figure 3 MMTT response; 2h blood glucose (A) and 2h serum insulin secretion AUC (B) after MMTTS
Figure 4 β-cell glucose sensitivity; A) Dose-response curve of insulin secretion rate and blood glucose concentration during a series of MMTT
Figure 4 β-cell glucose sensitivity; A) Dose-response curve of insulin secretion rate and blood glucose concentration during a series of MMTT
Figure 5 Evaluation of the additional effects of imatinib on β-cell function and metabolism
Figure 5 Evaluation of the additional effects of imatinib on β-cell function and metabolism
Table Adverse events with severity level 2 or more
Table Adverse events with severity level 2 or moreConclusion: A 26-week course of imatinib preserved β-cell function in newly-onset type 1 diabetic adults at 12 months
The 26-week course of imatinib preserved β-cell function in newly-onset type 1 diabetic adults at 12 months
Gitelman SE, Bundy BN, Ferrannini E,et al.
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
in this message
